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ported data. The objective of this study was to estimate persistence to oral bispho-
sphonates (OBPs) in the Portuguese postmenopausal osteoporosis (PMO) popula-
tion, exploring different methods. METHODS: This was an observational,
prospective cohort study of women 50 years old with PMO who had not been
prescribed PMO treatment within 6 months prior to recruitment from community
pharmacies. Patients were classified as persistent if they refilled their prescription
within a 30-day grace period after exhausting the time covered by their previous
supply. For subgroup analysis, non-persistent patients were followed up by tele-
phone. Sensitivity analysis included 6 different methods, in particular, increasing
the grace period to 90 days and allowing a switch to other PMO medication.
RESULTS: A total of 427 women (mean age 65 years) were included in the analysis.
Persistence rates at 6 months of follow-up (interim analysis) varied from 27.6%
(95%CI 23.4%-32.0%) to 52.6% (95%CI 47.3%-57.6%) using pharmacy records exclu-
sively and additional patient report of BP acquisition in a different pharmacy (re-
ported by 113 of 269 patients), respectively. Allowing a longer grace period (90 days)
and switch to other PMO medications resulted in rates of 49.9% (95%CI 33.8%-64.0%)
and 28.6% (95%CI 24.3%-33.0%), respectively. CONCLUSIONS: Results at 6 months
showed a variation in persistence rate estimates depending on the method applied,
with increased estimates when self-reported data and longer grace periods were
used. Ongoing analysis will allow assessment of the impact of the different meth-
ods over longer follow-up periods.
PMS58
FREQUENCY OF ADMINISTRATION OF BIOLOGICS HAS AN IMPACT ON
TREATMENT DECISION MAKING
Chevalier P1, Black CM2, Lamotte M3, Crombach J4, Huismans J4, Rosiek R5, Fan T6
1IMS Health, Vilvoorde, Belgium, 2St. John’s University, Queens, NY, USA, 3IMS Health
Consulting Group, Vilvoorde, Belgium, 4Merck Sharp & Dohme Netherlands, Haarlem, The
Netherlands, 5Medithuis B.V., MAARSSEN, BB , The Netherlands, 6Merck & Co. Inc., Whitehouse
Station, NJ, USA
OBJECTIVES: To document the real-life use of golimumab in patients with Anky-
losing spondylitis (AS), Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA), in
terms of treatment persistence/ discontinuation, adherence and switching
patterns. METHODS: This study was a single country (the Netherlands), retrospec-
tive database study of AS, RA and PsA patients treated with golimumab from March
17, 2010 onwards with last data collection being performed on October 3rd 2011.
RESULTS: The sample consisted of 882 patients (163 with AS, 216 with PsA and 503
with RA; 33% being male patients) with a maximum follow-up period of 57 weeks.
Forty-eight percent (n422) were naïve patients, while 52% (n460) were switched
from a previous anti-TNF treatment; 37% were previously treated with etanercept
and 38% with adalimumab, with no significant difference between the three indi-
cation groups. Among the switched patients, the main reason for switching to
golimumab were the lack of efficacy of the previous treatment (30.9%), the more
convenient frequency of administration with golimumab (27.0%) and unspecified
side-effects (18.8%). Temporary treatment discontinuation of golimumab was ob-
served in only 1.25% of the patients (n11). For these patients, adherence ranged
between 31.82% and 93.72%. The median time-to-dropout or median persistence
was 195 days when calculated in the whole population (n882). Sex and type of
patient (“naïve” vs. “switcher”) were identified as predictors, with a hazard ratio of
0.693 associated to male patients (vs. female patients; p-value0.014) and of 0.596
associated to naïve patients (vs. switchers; p-value0.001). CONCLUSIONS: Con-
venient frequency of administration has an impact on treatment decision making.
Sex and type of patient (“naïve” vs. “switcher”) were identified as predictors of
switch, with male patients and naïve patients associated with a higher persistence
to golimumab.
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OBJECTIVES: Comorbidities can influence generic measurement of health by
multi-attributes or indirect utility. We investigated the impact of comorbidities to
assess indirect utility with the Medical Outcomes Study Short Form 6D (SF-6D)
measuring health-related quality of life in patients with osteoarthritis (OA).
METHODS: The 878 patients, aged 45-75 years with symptomatic knee or/and hip,
of the KHOALA (Knee and Hip OsteoArthritis Long term assessment) cohort were
included in the study. Comorbidities were assessed by the Functional Comorbidity
Index (FCI) and grouped in 9 categories. Limitation in activities and pain was mea-
sured by the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC).Two separate linear regression models, using the number of comorbidi-
ties or the different categories of comorbidities of the FCI, were fitted to determine
predictors of utility score. RESULTS: For the 878 patients included, the mean (SD)
utility score was 0.66 (11; range 0.32–1.00) and mean number of comorbidities 2.05
(1.58). In the first multivariate model, , for each additional comorbidity (range 0–9) the
mean utility score decreased of 0.01 point (beta -0.010, p0.0001). In the second
model, including comorbidities by categories, only psychiatric disease (beta-
0.043, p0.0001) and degenerative disc disease (beta-0.014, p0.018) predicted
low utility score. In both regression models a worsened function (increased
WOMAC function score) significantly decreased the utility score. The number of
comorbidities explained 2% of the variance in utility score (partial R-square0.02)
and psychiatric and degenerative disc diseases explained 2% (partial
R-square0.025) and 0.7% (partial R-square0.007), respectively, of the variance in
utility score, whereas the WOMAC function score explained 38% of the variance in
both models (partial R-square  0.38). CONCLUSIONS: Compared to greater nega-
tive effect of functional impairment, comorbidities have a negative but relatively
marginal impact on indirect utility score. This suggests that clinically, considering
the functional severity of OA remains a first priority.
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OBJECTIVES: In time trade-off (TTO) and standard gamble (SG) procedures for elic-
iting health state utilities, the duration of time spent in each health state is an
integral component of the task. The most common time horizon is 10 years, but
others are used, including personalized time horizons which aim to present real-
istic choices reflecting reasonable expectations of the respondent’s lifespan. The
purpose of this study was to examine implications of the time horizon used in
direct utility assessment.METHODS:UK general population participants rated four
health states (describing osteoarthritis) with a Visual Analog Scale (VAS), followed
by TTO and SG procedures with a 10-year time horizon. Half of the sample was
randomized to complete utility procedures again with a personalized time horizon
based on self-reported additional life expectancy. Scores were compared in terms
of discrimination between health states. RESULTS: The 10-year tasks were com-
pleted by 80 participants (mean age 47.3; 48.8% female), and 35 also completed
personalized time horizon procedures. Nearly all participants (97.5%) rated health
state A (mild osteoarthritis) higher than B (moderate) on the VAS. However, the
10-year tasks did not consistently detect this ranking, with only 32.5% (TTO) and
23.1% (SG) of respondents distinguishing between health states. The personalized
time horizon resulted in increased rates of discrimination between health states:
54.3% with both TTO and SG. This increase was statistically significant (TTO: chi-
square 4.9; p 0.03; SG: chi-square 10.7; p 0.001). Two other health state pairs
followed similar patterns, but without statistically significant differences between
time horizons. CONCLUSIONS: In this exploratory study, the personalized time
horizon resulted in better discrimination between health states than the fixed
10-year approach. When designing utility evaluations, researchers should carefully
consider the time horizon so that the relative value of health states are accurately
represented in cost-utility models.
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OBJECTIVES: To compare health utility estimated with the EQ-5D and the Time-
trade-off (TTO) instruments after vertebral fracture. METHODS: The International
Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is a prospec-
tive multinational study with the aim of estimating costs and health related quality
of life (HRQoL) related to osteoporotic fractures. In the study, two instruments were
used to estimate patients’ perceived health utility: the direct individual preference
based TTO instrument and the indirect EQ-5D instrument, valued by societal pref-
erences. Health utility was measured before fracture (recollection), and 2 weeks, 4
months and 12 months after fracture. RESULTS: In the 225 patients included in the
interim analysis, estimates of health utility elicited from the two instruments var-
ied significantly and the EQ-5D systematically provided lower estimates compared
to the direct TTO instrument. The smallest mean outcome difference was 0.10
(TTO: 0.91 and EQ-5D: 0.81), elicited before fracture and the largest difference was
0.20 (TTO: 0.44 and EQ-5D: 0.23), elicited after two weeks. The correlation coeffi-
cient for the health utility loss over 12 months, using Spearman’s correlation, for
the two instruments was 0.36 (p0.05). CONCLUSIONS: Osteoporotic vertebral
fractures give rise to significant loss of health utility, irrespective of instrument
used. However, there are substantial differences in the extent of the health utility
decrease assessed by the two instruments. The main explanation for these differ-
ences is that the instruments rely on different reference populations; respondents
of direct TTO act as their own reference and express preferences regarding their
own health state, whereas the EQ-5D reflects the preferences of healthy individuals
assessing hypothetical health states.
PMS62
NOMINAL GROUP TECHNIQUE TO SELECT ATTRIBUTES FOR DISCRETE CHOICE
EXPERIMENTS
Hiligsmann M1, Van durme C1, Geusens P1, Dellaert B2, Dirksen C1, Van der Weijden T1,
Reginster JY3, Boonen A1
1Maastricht University, Maastricht, The Netherlands, 2Erasmus University Rotterdam,
Rotterdam, The Netherlands, 3University of Liège, Liège, Belgium
OBJECTIVES: The selection of attributes represents an important step in the devel-
opment of discrete-choice experiments (DCE), but is often poorly reported. In some
situations, the number of identified attributes may exceed what one may find
possible to pilot in a DCE. Hence there is a need to gain insight into methods to
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select attributes in order to construct the final list of attributes. This study aims to
test the feasibility of using the nominal group technique (NGT) to select attributes
for DCEs. METHODS: Patients group discussions (4-8 participants) were conducted
in Belgium and the Netherlands to prioritize a list of twelve potentially important
attributes for osteoporosis drug therapy that were retrieved from literature review
and expert discussions. The NGT consisted of three steps: 1) an individual ranking
of the twelve attributes by importance from 1 to 12; 2) a group discussion on each of
the attributes including a group review of the aggregate score of the initial rank-
ings; and 3) a second ranking task of the same attributes. The selection of attributes
for the DCE was based on groups’ ranking and NGT discussions followed by experts’
discussion. RESULTS: In total, 26 osteoporotic patients participated in five nominal
group sessions. Most (80%) patients changed their ranking after the discussion.
However, the average initial and final ranking did not markedly differ, with two
exceptions. In the final rank, the most important medication attributes were effec-
tiveness, side-effects, frequency and mode of administration. It was also observed
that some (15%) patients did not correctly rank from 1 to 12, and the order of
attributes did play a role in the ranking. CONCLUSIONS: The nominal group tech-
nique is feasible and useful for selecting attributes for DCE, although the ranking
task may be cognitively difficult and attributes order should vary over different
NGT sessions.
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OBJECTIVES: To assess the factors that most predicts diabetic patients’ self-effi-
cacy toward osteoporosis with respect to dietary calcium and physical exercise
activity. METHODS: A cross sectional study was undertaken in 250 diabetic type 2
outpatients (T2DM) over a 3-month period in 2011. A pre-validated questionnaire
was administered to assess osteoporosis knowledge tool (OKT-M, two subscale:
exercise and calcium), osteoporosis health behaviour scale (OHBS-M, seven sub-
scales: perceived susceptibility, perceived seriousness, barriers to calcium intake,
barriers to exercise, benefits of calcium intake, benefits of exercise, and health
motivation), osteoporosis risk factor and other demographic questionnaires prior
to the Malaysian osteoporosis self-efficacy scale (OSES-M, two subscale: calcium
and exercise). Then differences, correlations and multiple regressions were exam-
ined in relation to the demographic data, OKT-M and OHBS-M. RESULTS: There
were significant differences in the independent variables: education and income in
relation to OSES-M total scores. Correlations were performed to determine the
relationship between the two dependent variables (OSES-M calcium and exercise
subscale) and the OKT-M and OHBS-M. The OKT-M calcium and exercise subscale,
health motivation and perceived benefits for exercise were positively correlated
with both OSES-M exercise and calcium intake. While perceived benefits for cal-
cium intake was positively correlated with OSES-M exercise only. Perceived barrier
for calcium intake was negatively correlated with self-efficacy for exercise and
calcium. Regression analysis revealed that knowledge, health belief and some de-
mographic data had an impact on OSES-M and the R2scores value were 0.260 and
0.309 for calcium and exercise self-efficacy, respectively. CONCLUSIONS: The pres-
ent study findings suggested that assessing factors affecting the self-efficacy be-
haviour related to bone loss in diabetic patients will raised the potential impor-
tance of these components in the overall understanding of other diabetic
complications and for development of early screening and prevention of osteopo-
rosis in T2DM patients.
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OBJECTIVES: Head to head data from randomized controlled trials (RCTs) compar-
ing biologic monotherapies is limited. Our objective was to compare PROs for to-
cilizumab monotherapy vs. other approved biologic monotherapies, in DMARD-IR
RA patients, based on currently available RCT evidence. METHODS: Full-text pub-
lications of RCTs that assessed tocilizumab, and other biologic therapies, as mono-
therapy in DMARD-IR patients were identified through a systematic literature re-
view. RCTs reporting data on PROs (Health Assessment Questionnaire Disability
Index (HAQ-DI), pain VAS, patient global assessment of disease activity (PGA) VAS,
SF-36, or fatigue) at 24 weeks were included. Where sufficient data was available,
Bayesian network meta-analyses was used to obtain treatment effect estimates
between included interventions. It was assumed that the effects of the aTNF treat-
ments were exchangeable, and data for the assessed aTNFs were pooled to give a
single, more stable estimate. RESULTS: Four studies were identified that formed a
network comparing monotherapy treatments (tocilizumab and aTNFs (adali-
mumab, etanercept, certolizumab pegol)) and reported PRO data. Data on pain VAS,
PGA VAS, and HAQ-DI was most commonly reported. Tocilizumab monotherapy
showed greater improvement in pain [Difference -11.38 (95% CrI -18.40, -4.32)] and
PGA [Difference -10.49 (95% CrI -17.68, -3.24)] compared to the assessed aTNF
monotherapies. Tocilizumab monotherapy showed greater improvement in
HAQ-DI [Difference -0.52 (95% CrI -0.73, -0.31)] compared with placebo, and was at
least as efficacious compared to aTNF monotherapy [Difference -0.16 (95% CrI -0.33,
0.01)]. Insufficient data was reported for the SF-36 and fatigue to allow network
meta-analysis.CONCLUSIONS: Based on network meta-analysis of currently avail-
able RCT evidence, involving indirect comparison of trial findings, tocilizumab
monotherapy was found to have better outcomes than assessed aTNF monothera-
pies in terms of patient reported pain and disease activity in a DMARD-IR RA
population. Tocilizumab was at least as efficacious as aTNF agents in improvement
in physical function.
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OBJECTIVES: To validate and determine the discriminative power of the
FibroDetect®screening tool in helping primary care physicians detect patients with
fibromyalgia in routine practice.METHODS: The FibroDetect included 14 questions
assessing patients’ pain and fatigue, personal history and attitudes, symptoms and
impact on lives. To discriminate between American College of Rheumatology pos-
itive (ACR) patients and ACR negative (ACR-) patients (n276), a scoring method
was created using an iterative process based on statistical and clinical consider-
ations. The discriminant model was then validated with fibromyalgia and non-
fibromyalgia patients (n312). A score threshold for individual ACR classification
was defined. RESULTS:Of the 14 original FibroDetect questions, six questions were
retained in the final scoring, demonstrating discriminative power between ACR
and ACR- patients with an area under the ROC curve of 0.74. A majority of ACR
patients (77%) and less than half of ACR– (39%) had a score  6, suggesting that
patients with such score are likely to be ACR, and should thus be referred to a
fibromyalgia specialist. A total of 8% of ACR patients and 79% of ACR– patients
had a score 3, suggesting that patients with such score were unlikely to be ACR,
and should thus be not be referred to a fibromyalgia specialist. Patients with a
FibroDetect score of 4 or 5 would require further investigation. The predictive ac-
curacy of the tool increased to 0.86 for fibromyalgia and non-fibromyalgia patient
detection. With a 6-point cut-off, the sensitivity was 90% and the specificity was
67% for fibromyalgia and non-fibromyalgia patient detection. CONCLUSIONS: The
FibroDetect is a screening tool that detects potential fibromyalgia patients among
patients with chronic widespread pain. It can be used as a surrogate for ACR clas-
sification criteria in primary care settings, and improve referral to appropriate
specialist.
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OBJECTIVES: Myotonic dystrophy type-1 (DM1) is a dominantly inherited disorder
caused by an unstable CTG repeat expansion on chromosome 19. Clinically the
disease is associated with a wide variety of symptoms. The Myotonic Dystrophy
Health Index (MDHI) is a disease-specific patient reported outcome measure de-
signed to measure total health, and 17 of the most important areas of disease-
specific health in DM1. The items in this instrument were selected utilizing quali-
tative interviews and a cross-sectional study of 278 patients. The MDHI’s total score
(and each of the 17 subscales) are scored from 0-100 with 100 representing the
highest level of disease. The objective of this research is to evaluate the MDHI’s
ability to differentiate between known groups of DM1 patients. METHODS: Each of
the MDHI’s 17 subscales was completed by a group of DM1 patients. DM1 respon-
dents were divided into known groups by employment status, CTG repeat number
(300,300), education (non-college graduate, college graduate), age (21-46,47
years), and duration of symptoms (21,21 years). The average subscale score and
total MDHI score was calculated for each known group. RESULTS: On average, 138
DM1 patients completed each subscale. The MDHI measured a higher disease bur-
den in patients who were unemployed (MDHI total score: 41.5 vs. 25.0), less edu-
cated (41.4 vs. 33.8), had a longer duration of symptoms (41.3 vs. 34.6), were of older
age (38.3 vs. 33.1) and those with a longer CTG repeat number (35.6 vs. 27.6).
CONCLUSIONS: The MDHI and its subscales are capable of differentiating between
known groups of DM1 patients who are suspected of having a higher burden of
disease.
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